Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes

Kidney International

Volumn 52, Issue 1, 1997, Pages 10-20

  Bostom, Andrew G ^a   Lathrop, Lori ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Arteriosclerosis; Cardiovascular disease risk factor; End stage renal disease; Hyperhomocyteinemia

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; VITAMIN B GROUP;

ARTERIOSCLEROSIS; CLINICAL TRIAL; DIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; REVIEW;

EID: 0030762686     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1997.298     Document Type: Article

References (112)

1. EXCERPTS FROM THE UNITED STATES RENAL DATA SYSTEM, UNITED STATES RENAL DATA SYSTEM: Annual Report. Am J Kid Dis 26(Suppl 2):S85-S94, 1995
2. CHURCHILL DN: Comparative morbidity among hemodialysis and continuous ambulatory peritoneal dialysis patients. Kidney Int 43(Suppl):S16-S22, 1993
3. CANADA-USA (CANUSA) PERITONEAL DIALYSIS STUDY GROUP: Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes. J Am Soc Nephrol 7:198-207, 1996
4. LEMMERS MJ, BARRY JM: Major role for arterial disease in morbidity and mortality after kidney transplantation in diabetic recipients. Diabetes Care 14:295-301, 1991
5. KASISKE BL, GUIJARRO C, MASSY Z, WIEDERKEHR MR, MA JZ: Cardiovascular disease after renal transplantation. J Am Soc Nephrol 7:158-165, 1996
6. WILSON PWF, CASTELLI WP, KANNEL WB: Coronary risk prediction in adults (the Framingham Heart Study). Am J Cardiol 59:91G-94G, 1987
7. MA KW, GREENE EL, RAIJ L: Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kid Dis 19:505-513, 1992
8. ROSTAND SG, KIRK KA, RUTSKY EA: Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. Kidney Int 22:304-308, 1982
9. CRESSMAN MD, HEYKA RJ, PAGANINI EP, O'NEILL J, SKIBINSKI CI, HOFF HF: Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482, 1992
10. WU G: Cardiovascular deaths among CAPD patients. Perit Dial Bull 4(Suppl):S23-S25, 1983
11. FOLLY RN, PARFREY PS, HARNETT JD, KENT GM, MURRAY DC, BARRE PE: Impact of hypertension on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Kidney Int 49:1379-1385, 1996
12. BOSTOM AG, SHEMIN D, LAPANE KL, SUTHERLAND P, NADEAU MR, WILSON PWF, YOBURN D, BAUSSERMAN L, TOFLER G, JACQUES PF, SELHUB J, ROSENBERG IH: Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study. Atherosclerosis 125:91-101, 1996
13. MCCULLY KS: Vascular pathology of homocysteinemia: implications for pathogenesis of arteriosclerosis. Am J Pathol 56:111-128, 1969
14. STAMPFER MJ, MALINOW MR, WILLET WC, NEWCOMKR LM, UPSON B, ULLMAN D, TISHLER PV, HENNEKENS CH: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 268:877-881, 1992
15. BOSTOM AG, SHEMIN D, VERHOEF P, NADEAU MR, JACQUES PF, SELHUB J, DWORKIN L, ROSENBERG IH: Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study. Arteriosclerosis Thromb Vasc Biol (in press)
16. BROSNAN JT: The 1986 Borden Award Lecture. The role of the kidney in amino acid metabolism and nutrition. Can J Physiol Pharmacol 65:2355-2362, 1987
17. TIZIANELLO A, DE FERRARI G, GARIBOTTO G, GURRERI G, ROBAUDO C: Renal metabolism of amino acids and ammonia in subjects with normal renal function and in patients with chronic renal insufficiency. J Clin Invest 65:1162-1173, 1980
18. FLUGEL-LINK RM, JONES MR, KOPPLE JD: Red cell and plasma amino acid concentrations in renal failure. J Puren Ent Nutr 7:450-456, 1983
19. LAIDLAW SA, BERG RL, KOPPLE JD, NAITO H, WALKER WG, WALSER M: Patterns of fasting plasma amino acid levels in chronic renal insufficiency: Results from the feasibility phase of the Modification of Diet in Renal Disease Study. Am J Kid Dis 23:504-513, 1994
20. BOSTOM AG, BROSNAN JT, HALL B, NADEAU MR, SELHUB J: Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 116:59-62, 1995
21. SELHUB J, MILLER JW: The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by s-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 55:131-138, 1992
22. MCKEEVER MP, WEIR DG, MOLLOY A, SCOTT JM: Betaine: Homocysteine methyltransferase: organ distribution in man, pig, and rat and subcellular distribution in the rat. Clin Sci 81:551-556, 1991
23. UELAND PM, REFSUM H, STABLER SP, MALINOW MR, ANDERSSON A, ALLEN RH: Total homocysteine in plasma or serum: methods and applications. Clin Chem 39:1764-1773, 1993
24. MUDD SH, LEVY HL, SKOVBY F: Disorders of transsulfuration, in Metabolic Basis of Inherited Disease (6th ed), edited by SCRIVER CR, BEAUDET AL, SLY WS, VALLE D, New York, McGraw Hill, Inc., 1989, pp 693-734
25. ROSENBLATT DS: Inherited disorders of folate transport and metabolism, in Metabolic Basis of Inherited Disease (6th ed), edited by SCRIVER CR, BEAUDET AL, SLY WS, VALLE D, New York, McGraw Hill, Inc., 1989, pp 2049-2064
26. LINNELL JC, BHATT HR: Inherited disorders of cobalamin metabolism and their management. Ballières Clin Haematol 8:567-601, 1995
27. BRATTSTROM L, ISRAELSSON B, HULTBERG B: Plasma homocysteine and methionine tolerance in early-onset vascular disease. Haemostasis 19(Suppl 1):35-44, 1989
28. MILLER JW, NADEAU MR, SMITH J, SMITH D, SELHUB J: Folate deficiency-induced homocysteinemia in rats: Disruption of S-adenosylmethionine's coordinate regulation of homocysteine metabolism. Biochem J 298:415-419, 1994
29. MILLER JW, NADEAU MR, SMITH D, SELHUB J: Vitamin B-6 deficiency vs. folate deficiency: comparison of responses to methionine loading in rats. Am J Clin Nutr 59:1033-1039, 1994
30. BOSTOM AG, JACQUES PF, NADEAU MR, WILLIAMS RR, ELLISON RC, SELHUB J: Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study. Atherosclerosis 116:147-151, 1995
31. BOSTOM AG, ROUBENOFF R, DELLARIPA P, NADEAU MR, SUTHERLAND P, WILSON PW, JACQUES PF, SELHUB J, ROSENBERG IH: Validation of abbreviated oral methionine loading test. Clin Chem 41:948-949, 1995
32. SELHUB J, JACCOUES PF, WILSON PWF, RUSH D, ROSENBERG IH: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270:2693-2697, 1993
33. JACQUES PF, BOSTOM AG, WILLIAMS RR, ELLISON RC, ECKFELDT JH, ROSENBERG IH, SELHUB J, ROZEN R: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93:7-9, 1996
34. GOYETTE P, SUMNER JS, MILOS R, DUNCAN MV, ROSENBLATT DS, MATTHEWS RG, ROZEN R: Human methylenetetrahydrofolate reductase: Isolation of cDNA, mapping, and mutation identification. Nature Genet 7:195-200, 1994
35. FROSST P, BLOM HJ, MILOS R, GOYETTE P, SHEPPARD CA, MATTHEWS RG, BOERS GJH, DEN HEIJER M, KLUIJTMANS LAJ, VAN DEN HEUVEL LP, ROZEN R: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nature Genet 10:111-113, 1995
36. BRATTSTROM L, LINDGREN A, ISRAELSSON B, ANDERSSON A, HULTBERG B: Homocysteine and cysteine: Determinants of plasma levels in middle-aged to elderly subjects. J Intern Med 236:633-641, 1994
37. ARAKI A, SAKO Y, FUKUSHIMA Y, MATSUMOTO M, ASADA T, KITA T: Plasma sulfhydryl amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis 79:139-146, 1989
38. Wu LL, WU J, HUNT SC, JAMES BC, VINCENT GM, WILLIAMS RR, HOPKINS PN: Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem 40:552-561, 1994
39. LUSSIER-CACAN, XHIGNESSE M, PIOLOT A, SELHUB J, DAVIGNON J, GENEST JJ JR: Plasma total homocysteine in healthy subjects: Sexspecific relation with biological traits. Am J Clin Nutr 64:587-593, 1996
40. MUDD SH, POOLE JR: Labile methyl balances for normal humans on various dietary regimens. Metabolism 24:721-735, 1975
41. LINDGREN A, BRATTSTROM L, NORRVING B, HULTBERG B, ANDERSSON A, JOHANSSON BB: Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 26:795-800, 1995
42. ROBINS AJ, MILEWCZYK BK, BOOTH EM, MALLICK NP: Plasma amino acid abnormalities in chronic renal failure. Clin Chim Acta 42:215-217, 1972
43. COHEN BD, PATEL H, KORNHAUSER RS: Alternate reasons for atherogenesis in uremia. Proc Dial Transplant Forum 7:178-180, 1977
44. WILCKEN DEL, GUPTA VJ: Sulphur-containing amino acids in chronic renal failure with particular reference to cysteine-homocysteine mixed disulfide. Eur J Clin Invest 9:301-307, 1979
45. WILCKEN DEL, GUPTA VJ: Accumulation of sulphur-containing amino acids including cysteine-homocysteine mixed disulfide in patients on hemodialysis. Clin Sci 58:427-431, 1980
46. WILCKEN DEL, GUPTA VJ, BETTS AK: Homocysteine in the plasma of renal transplant recipients: Effects of cofactors for methionine metabolism. Clin Sci 61:743-749, 1981
47. KANG SS, WONG PWK, BIDANI A, MILANEZ S: Plasma protein-bound homocyst(e)ine in patients requiring chronic hemodialysis. Clin Sci 65:335-337, 1983
48. SMOLIN LA, LAIDLAW SA, KOPPLE JD: Altered plasma free and protein-bound sulfur amino acid levels in patients undrgoing maintenance hemodialysis. Am J Clin Nutr 45:737-743, 1987
49. CHAUVEAU P, CHADEFAUX B, COUDÉ M, AUPETIT J, HANNEDOUCHE T, KAMOUN P, JUNGERS P: Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 43:(Suppl 41) S72-S77, 1993
50. HULTBERG B, ANDERSSON A, STERNER G: Plasma homocysteine in renal failure. Clin Nephrol 40:230-234, 1993
51. STABLER SP, LINDENBAUM J, SAVAGE DG, ALLEN RH: Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. Blood 81:3404-3413, 1993
52. KIM SS, HIROSE S, TAMURA H, NAGASAWA R, TOKUSHIMA H, MITARAI T, ISODA K: Hyperhomocysteinemia as a possible role for atherosclerosis in CAPD patients. Adv Perit Dial 10:282-285, 1994
53. MASSY ZA, CHADEFAUX-VEKEMANS B, CHEVALIER A, BADER CA, DRUEKE TB, LEGENDRE C, LACOUR B, KAMOUN P, KREIS H: Hyperhomocysteinemia: A significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 9:1103-1108, 1994
54. BOSTOM AG, SHEMIN D, LAPANE KL, MILLER JW, SUTHERLAND P, NADEAU MR, SEYOUM E, HARTMAN W, PRIOR R, WILSON WF, SELHUB J: Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case control study. Atherosclerosis 114:93-103, 1995
55. PERNA AF, INGROSSO D, DE SANTO NG, GALLETTI P, ZAPPIA V: Mechanism of erythrocyte accumulation of methylation inhibitor s-adenosylhomocysteine in uremia. Kidney Int 47:247-253, 1995
56. BACHMANN J, TEPEL M, RAIDT H, RIEZLER R, GRAEFE U, LANGER K, ZIDEK W: Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 6:121-125, 1995
57. ARNADOTTIR M, HULTBERG B, VLADOV V, NILSSON-EHLE P, THYSELL H: Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 61:509-512, 1996
58. ROBINSON K, GUPTA A, DENNIS V, ARHEART K, CHAUDHARY D, GREEN R, VIGO P, MAYER EL, SELHUB J, KUTNER M, JACOBSEN DW: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94:2743-2748, 1996
59. DESCOMBES E, HANCK AB, FELLAY G: Water soluble vitamins in chronic hemodialysis patients and need for supplementation. Kidney Int 43:1319-1323; 1993
60. SPANNUTH CL, WARNOCK LG, WAGNER C, STONE WJ: Increased plasma clearance of pyridoxal 5′-phosphate in vitamin B-6 deficient uremic man. J Lab Clin Invest 90:632-637, 1977
61. WEI I-L, YOUNG T-K: Activities of hepatic vitamin B-6 metabolizing enzymes and concentrations of vitamin B-6 vitamers in tissues of chronically azotemic rats. J Nutr Biochem 6:494-498, 1995
62. BOSTOM AG, SHEMIN D, LAPANE KL, NADEAU MR, SUTHERLAND P, CHAN J, ROZEN R, YOBURN D, JACQUES PF, SELHUB J, ROSENBERG IH: Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 123:193-202, 1996
63. JANSSEN MJFM, VAN GULDENER C, DE JONG GMT, VAN DEN BERG M, STEHOUWER CDA, DONKER AJM: Folic acid treatment of hyperhomocysteinemia in dialysis patients. Miner Electrol Metab 22:110-114, 1996
64. BOSTOM AG, SHEMIN D, YOBURN D, FISHER DH, NADEAU MR, SELHUB J: Brief report: Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients. Atherosclerosis 120:242-244, 1996
65. ZAZGORNIK J, DRUML W, BALCKE P, KOPSA H, MAROSI L, NEUMANN E, SCHMIDT P: Diminished serum folic acid levels in renal transplant recipients. Clin Nephrol 18:306-310, 1982
66. LACOUR B, PARRY C, DRUEKE T, TOUAM M, KREIS H, BAILLY M, DURAND D: Pyridoxal 5′-phosphate deficiency in uremic undialyzed. hemodialyzed, and non-uremic kidney transplant patients. Clin Chim Acta 127:205-215, 1983
67. STABLER SP, MARCELL PD, PODELL ER, ALLEN RH: Quantitation of total homocysteine, total cysteine, and methionine in normal serum and urine using gas chromatography-mass spectrometry. Anal Biochem 162:186-196, 1988
68. BRATTSTROM L, LINDGREN A, ISRAELSSON B, MALINOW MR, NORRVING B, UPSON B, HAMFELT A: Hyperhomocysteinemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. EurJ Clin Invest 22:214-221, 1992
69. GUTTORMSEN AB, SCHNEEDE J, UELAND PM, REFSUM H: Kinetics of total plasma homocysteine in subjects with hyperhomocysteinemia due to folate or cobalamin deficiency. Am J Clin Nutr 63:194-202, 1996
70. FOREMAN JW, WALD H, BLUMBERG G, PEPE LM, SEGAL S: Homocysteine uptake in isolated rat renal cortical tubules. Metabolism 31:613-619, 1982
71. BOCOCK MA, ZLOTKIN SH: Hepatic sulfur amino acid metabolism in rats with chronic renal failure. J Nutr 120:691-699, 1990
72. GUTTORMSEN AB, UELAND PM, SVARSTAD E, REFSUM H: The kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int (in press)
73. STURMAN JA, GAULL GE, NIEMANN WH: Activities of some enzymes involved in homocysteine methylation in brain, liver, and kidney of the developing rhesus monkey. J Neurochem 27:425-431, 1976
74. GAULL GE, VON BERG W, RAIMA NCR, STURMAN JA: Development of methyltransferase activities of human fetal tissues. Pediatr Res 7:527-533, 1973
75. STURMAN JA, RASSIN DK, GAULL GE: Distribution of transsulfuration enzymes in various organs and species. Int J Biochem 1:251-253, 1970
76. VAN GULDENER C, JANSSEN MJFM, SURACHNO J: Short term effect of kidney transplantation on plasma homocysteine in dialysis patients, (abstract) Irish J Med Sci 164:22, 1995
77. ARNADOTTIR M, HULTBERG B, NILSSON-EHLE P, THYSELL H: The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 56:41-46, 1996
78. COCKROFT DW, GAULT MH: Prediction of creatinine clearance from serum creatinine. Nephron 16, 1976
79. BOUSHEY CJ, BERESFORD SAA, OMEN GS, MOTULSKY AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 274:1049-1057, 1995
80. ARNESEN E, REFSUM H, BONAA KH, UELAND PM, FORDE OH, NORDREHAUG JE: Serum total homocysteine and coronary heart disease. Int J Epidemiol 24:704-709, 1995
81. PERRY IJ, REFSUM H, MORRIS RW, EBRAHIM SB, UELAND PM, SHAPER AG: Serum total homocysteine and coronary heart disease in middle-aged British men. Heart 75(Suppl 1):P53, 1996
82. PERRY IJ, REFSUM H, MORRIS RW, EBRAHIM SB, UELAND PM, SHAPER AG: Prospective study of serum total homocysteine and risk of stroke in middle-aged British men. Lancet 346:1395-1398, 1995
83. GRAHAM IM, DALY LE, REFSUM HM, ROBINSON K, BRATTSTROM LE, UELAND PM, PALMA-REIS RJ, BOERS GHJ, SHEAHAN RG, ISRAELSON B, UITERWAAL CS, MELEADY RM: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA (in press)
84. HARKER LA, ROSS R, SLICHTER SJ, SCOTT CR: Homocystine-induced arteriosclerosis. The role of endothelial injury and platelet response in its genesis. J Clin Invest 58:731-741, 1976
85. WALL RT, HARLAN JM, HARKER LA, STRIKER GE: Homocystine-induced endothelial injury in vitro: A model for the study of vascular injury. Thromb Res 18:113-121, 1980
86. HEINECKE JW, ROSEN H, SUZUKI LA, CHAIT A: The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 262:10098-10103, 1987
87. DI MINNO G, DAVI G, MARGAGLIONE M, CIRILLO F, GRANDONE E, CIBATTONI G, CATALANO I, STRISCIUGLIO P, ANDRIA G, PATRONO C, MANCINI M: Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol sensitive mechanism. J Clin Invest 92:1400-1406, 1993
88. LENTZ SR, SADLER JE: Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 88:1906-1914, 1991
89. HARPEL PC, CHANG VT, BORTH W: Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: A potential link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 89:10193-10197, 1992
90. TSAI JC, PERRELLA MA, YOSHIZUMI M, HSIEH C-M, HABER E, SCHLEGEL R, LEE M-E: Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 91:6369-6373, 1994
91. DUDMAN NP, HICKS C, WANG J, WILCKEN DE: Human arterial endothelial cell detachment in vitro: its promotion by homocysteine and cysteine. Atherosclerosis 91:77-83, 1991
92. WANG J, DUDMAN NP, WILCKEN DE: Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells. Thromb Haemost 70:1047-1052, 1993
93. MANSOOR MA, UELAND PM, AARSLAND A, SVARDAI. AM: Redox status and protein binding of plasma homocysteine and other aminothiols in patients with homocystinuria. Metabolism 42:1481-1485, 1993
94. ROLLAND PH, FRIGGI A, BARLAITER A, PIQUET P, LATRILLE V, FAYE MM, ET AL: Hyperhomocyst(e)inemia-induced vascular damage in the minipig. Circulation 91:1161-1174, 1995
95. LENTZ SR, SOBEY CG, PIEGORS DJ, BHOPATKAR MY, FARACI FM, MALINOW MR, HEISTAD DD: Vascular dysfunction in monkeys with diet-induced hyperhomocysteinemia. J Clin Invest 98:24-29, 1996
96. MUDD SH, SKOVBY F, LEVY HL, PETTIGREW KD, WILCKEN B, PYERITZ RE, ANDRIA G, BOERS GH, BROMBERG IL, CERONE R, FOWLER B, GROBE H, SCHMIDT H, SCHWEITZER L: The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 37:1-31, 1985
97. BRATTSTROM LE, ISRAELSSON B, JKPPSSON J-O, HULTBLRG B: Folic acid- an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 48:215-221, 1988
98. GLUECK CJ, SHAW P, LANG JE, TRACY T, SIEVE-SMITH L, WANG Y: Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 132-136, 1995
99. UBBINK JB, VERMAAK WJH, VAN DER MERWE A, BECKER PJ: Vitamin B-12, vitamin B-6, folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 57:47-53, 1993
100. UBBINK JB, VERMAAK WJH, VAN DER MERWE A, BECKER PJ, DELPORT R, POTGEITER HC: Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 124:1927-1933, 1994
101. LANDGREN F, ISRAELSSON B, LINDGREN A, HULTBERG B, ANDERSSON A, BRATTSTROM L: Plasma homocysteine in acute myocardial infarction: Homocysteine-lowering effect of folic acid. J Intern Med 237: 381-388, 1995
102. BRATTSTROM L, ISRAELSSON B, LINDGARDE F, HULTBERG B: Higher total plasma homocysteine in vitamin B12 deficiency than in heterozygosity for homocystinuria due to cystathionine beta synthase deficiency. Metabolism 37:175-178, 1988
103. BRATTSTROM L, ISRAELSSON B, NORRVING B, BERQVIST D, THORNE J, HULTBERG B, HAMFELT A: Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease: Effects of pyridoxine and folic acid treatment. Atherosclerosis 81:51-60, 1990
104. FRANKEN DG, BOERS GHJ, BLOM HJ, TRIJBELS JMF: Effect of various regimens of vitamin B-6 and folic acid on mild hyperhomocysteinemia in vascular patients. J Inherit Metab Dis 17:159-162, 1994
105. UBBINK JB, VAN DER MERWE A, DELPORT R, ALLEN RH, STABLER SP, RIEZLER R, VERMAAK WJH: The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 98:177-184, 1996
106. BOSTOM AG, SHEMIN D, LAPANE KL, HUME AL, YOBURN D, NADEAU MR, BENDICH A, SELHUB J, ROSENBERG IH: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49:147-152, 1996
107. WILCKEN DEL, DUDMAN NP, TYRRELL PA, ROBERTSON MR: Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease. Metabolism 37:697-701, 1988
108. ARNADOTTIR M, BRATTSTROM L, SIMONSEN O, THYSSELL H, HULTBERG B, ANDERSSON A, NILSSON-EHLE P: The effect of high dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 40: 236-240, 1993
109. CHAUVEAU P, CHADEFAUX B, COUDE M, AUPETIT J, KAMOUN P, JUNGERS P: Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner Electrol Metab 22:106-109, 1996
110. BOSTOM AG, SHEMIN D, NADEAU MR, SHIM VE, STABLER SP, ALLEN RH, SELHUB J: Short term betaine therapy fails to lower elevated fasting total plasma homocysteine levels in hemodialysis patients maintained on chronic folic acid supplementation. Atherosclerosis 113:129-132, 1995
111. DENNIS VW, ROBINSON K: Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int 50(Suppl 57):S11-S17, 1996
112. BERGSTRÖM J: Nutrition and mortality in hemodialysis. J Am Soc Nephrol 6:1329-1341, 1995